NCT07159906 - Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 8, 2025

Primary Completion Date

August 1, 2027

Study Completion Date

August 1, 2028

Conditions

Diffuse Large B-Cell LymphomaRelapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma

Interventions

DRUG

Homoharringtonine

A cephalotaxine alkaloid and protein synthesis inhibitor that downregulates Myeloid Cell Leukemia 1 (MCL-1), administered intravenously in 21-day cycles. Dose escalation in Phase Ib will determine dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and recommended Phase II dose (RP2D).

DRUG

BCL-2 inhibitor

An oral selective BCL2 inhibitor administered once daily D1-7. Combined with homoharringtonine, rituximab, and prednisone in 21-day cycles.

DRUG

CD20 Antibody

An anti-CD20 monoclonal antibody administered intravenously, used in combination with chemotherapy or targeted regimens for B-cell malignancies.

DRUG

Glucocorticoid (GC)

glucocorticoid , given as part of the combination regimen to enhance anti-lymphoma effect.

Trial Locations (1)

310003

Department of Hematology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors

lead

First Affiliated Hospital of Zhejiang University

OTHER